Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).
Alberto F. Sobrero(Ospedale Policlinico San Martino), Roger Sidhu(Amgen (United States)), Florian Lordick(Leipzig University), Timothy Price(Basil Hetzel Institute), Thierry André(Inserm), Marc Peeters(University of Antwerp), Andrés Cervantes(INCLIVA Health Research Institute), Ying Tian(NARI Group (China)), Emily Chan(Ghent University Hospital), Michel Ducreux(Université Paris-Saclay), Yevhen Hotko(Ghent University Hospital)
Cited by 16
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k